ClinicalTrials.gg

Program

etakafusp alfa

Also written as “AB248” and “etakafusp alfa (AB248)”.

Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 1, since Jun 17, 20252 company-led studies, 2 open or runningNext primary completion: Mar 18, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen11 open or runningphase 1since Jun 17, 2025Jun 17, 2025Mar 18, 2028phase 1 · NCT07037758
Asher Biotherapeutics11 open or runningphase 1since Nov 30, 2022Nov 30, 2022none ahead

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2022First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Asher BiotherapeuticsAsher Biotherapeutics · NCT05653882 · 552 enrolled · United States
  2. Jun 17, 2025Amgen’s first study: phase 1 study in Extensive Stage Small Cell Lung CancerNew to AmgenAmgen · NCT07037758 · 380 planned · United States, South Korea, Turkey (Türkiye)

Ahead

  1. Mar 18, 2028Primary completion: phase 1 study in Extensive Stage Small Cell Lung CancerAmgen · NCT07037758

TargetBeta

CD8A →read by rule
“A recombinant fusion protein comprised of a humanized immunoglobulin G1 (IgG1) antibody targeting the T-cell surface glycoprotein CD8 beta chain (CD8b) ”NCIt, by rule

Other programs on CD8A

ProgramCompanyFurthest phaseStudies
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
CD8-guided IL-2 Fusion Protein AZD6750AstraZenecaphase 21
Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621AstraZenecaphase 21
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 21

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07037758Extensive Stage Small Cell Lung Cancer · United States, South Korea, Turkey (Türkiye)1RecruitingAmgenMar 18, 2028380
NCT05653882Carcinoma, Non-Small-Cell Lung · United States1Active, not recruitingAsher BiotherapeuticsAug 2026552

How it is read

Names in the registry

  • “AB248”, 1 entry
  • “etakafusp alfa (AB248)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.